Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01557946 · ClinicalTrials.gov registry record · Phase 4
Glutamatergic and GABAergic Mediators of Antidepressant Response in Major Depression
A Phase 4 study, sponsored by Mclean Hospital.
- Completed
- Registry status
- Phase 4
- Development phase
- 32
- Enrollment target
NCT01557946 is a Phase 4 study that has completed, run by Mclean Hospital. The registered enrollment target is 32 participants.
The verdict
NCT01557946, a Phase 4 study, has completed, sponsored by Mclean Hospital.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 32 participants
- Enrollment target
Study Summary
Primarily, this study seeks to evaluate whether citalopram treatment is associated with an increase in the Glutamine (Gln)/Glutamate (Glu) ratio in the anterior cingulate cortex (ACC) from baseline to day 3 of treatment. Additionally, this study would like to examine whether citalopram treatment is associated with an increase in the Gln/Glu ratio in the ACC from baseline to day 7 of treatment. In order to more fully examine baseline neurochemical and functional abnormalities in participants with MDD, we also seek to scan a group of age- and sex-matched non-depressed comparison individuals in order to perform between-group analyses of baseline neuroimaging measures.
Interventions
- DRUG citalopram
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2012-03 |
| Est. Completion | 2015-09 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01557946
The ClinicalTrials.gov registry entry for NCT01557946 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mclean Hospital, which has 140 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which citalopram is the first listed.
NCT01557946 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01557946 about?
NCT01557946 is a clinical study titled "Glutamatergic and GABAergic Mediators of Antidepressant Response in Major Depression". Primarily, this study seeks to evaluate whether citalopram treatment is associated with an increase in the Glutamine (Gln)/Glutamate (Glu) ratio in the anterior cingulate cortex (ACC) from baseline to day 3 of treatment. Additionally, this study would like to examine whether citalopram treatment is ...
What is the current status of trial NCT01557946?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 32 participants. The study started on 2012-03. Estimated completion is 2015-09.
What interventions are being tested in trial NCT01557946?
The interventions under investigation include: citalopram (DRUG).
Who is sponsoring clinical trial NCT01557946?
This trial is sponsored by Mclean Hospital, which has 140 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.